Bayer's Aleve 'Proven Better' Than Tylenol Claims Fail In J&J Challenge At NAD
Executive Summary
Bayer appeals to National Advertising Review Board over NAD’s finding the firm didn't support claims its Aleve OTC provides superior pain-relief to J&J’s Tylenol. It says NAD misunderstands scientific data and it will argue pain studies it submitted were methodologically sound and pain-relief statements were not overly broad.
You may also be interested in...
NAD Offers Complex And Fast Tracks: Not All Advertising Claim Reviews Are Alike
NAD will assign three attorneys at the beginning of each Complex Track review instead of one, director Laura Brett said in a recent interview. The industry self-regulation group also recently launched its Fast-Track program for more simple ad claim challenges that rarely have been made.
Disclosure Of Six-Hour Limit Clears Bayer To Claim Aleve ‘Better On Pain’ Than J&J's Tylenol
An appeals panel in the BBB National Programs, Inc. industry self-regulation program said Bayer should use a "six hour" qualifier with claims that its Aleve naproxen OTC is "better on pain" than J&J's Tylenol acetaminophen products.
Aleve Challenge, New Study Catch Up To Advil 'Works Longer' Claim In NAD Review
Although 1993 studies to make Aleve available OTC didn't support claiming the naproxen oral analgesic lasted longer than ibuprofen-containing Advil, 2018 study Bayer submitted for National Advertising Division review shows Advil's efficacy doesn't exceed Aleve's. Report also says while Pfizer criticized inpatient methodology of Bayer's study, inpatient is industry standard method for pain medication trials.